EBS vs. NVCR
Compare and contrast key facts about Emergent BioSolutions Inc. (EBS) and NovoCure Limited (NVCR).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EBS or NVCR.
Correlation
The correlation between EBS and NVCR is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
EBS vs. NVCR - Performance Comparison
Key characteristics
EBS:
0.24
NVCR:
0.10
EBS:
1.29
NVCR:
0.95
EBS:
1.17
NVCR:
1.11
EBS:
0.29
NVCR:
0.13
EBS:
0.68
NVCR:
0.40
EBS:
41.77%
NVCR:
29.90%
EBS:
124.84%
NVCR:
81.54%
EBS:
-98.89%
NVCR:
-95.07%
EBS:
-95.81%
NVCR:
-92.30%
Fundamentals
EBS:
$268.97M
NVCR:
$2.02B
EBS:
-$3.60
NVCR:
-$1.51
EBS:
1.55
NVCR:
-0.47
EBS:
0.26
NVCR:
3.22
EBS:
0.58
NVCR:
5.53
EBS:
$737.80M
NVCR:
$621.71M
EBS:
$181.00M
NVCR:
$479.70M
EBS:
-$26.50M
NVCR:
-$105.45M
Returns By Period
The year-to-date returns for both stocks are quite close, with EBS having a -40.90% return and NVCR slightly lower at -41.68%.
EBS
-40.90%
20.47%
-52.00%
29.29%
-41.33%
-14.49%
NVCR
-41.68%
2.54%
-0.34%
7.75%
-22.57%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EBS vs. NVCR — Risk-Adjusted Performance Rank
EBS
NVCR
EBS vs. NVCR - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and NovoCure Limited (NVCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
EBS vs. NVCR - Dividend Comparison
Neither EBS nor NVCR has paid dividends to shareholders.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
EBS Emergent BioSolutions Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.65% |
NVCR NovoCure Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
EBS vs. NVCR - Drawdown Comparison
The maximum EBS drawdown since its inception was -98.89%, roughly equal to the maximum NVCR drawdown of -95.07%. Use the drawdown chart below to compare losses from any high point for EBS and NVCR. For additional features, visit the drawdowns tool.
Volatility
EBS vs. NVCR - Volatility Comparison
Emergent BioSolutions Inc. (EBS) has a higher volatility of 37.43% compared to NovoCure Limited (NVCR) at 16.62%. This indicates that EBS's price experiences larger fluctuations and is considered to be riskier than NVCR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
EBS vs. NVCR - Financials Comparison
This section allows you to compare key financial metrics between Emergent BioSolutions Inc. and NovoCure Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EBS vs. NVCR - Profitability Comparison
EBS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported a gross profit of 71.30M and revenue of 189.30M. Therefore, the gross margin over that period was 37.7%.
NVCR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, NovoCure Limited reported a gross profit of 116.47M and revenue of 154.99M. Therefore, the gross margin over that period was 75.2%.
EBS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported an operating income of -9.50M and revenue of 189.30M, resulting in an operating margin of -5.0%.
NVCR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, NovoCure Limited reported an operating income of -37.87M and revenue of 154.99M, resulting in an operating margin of -24.4%.
EBS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported a net income of -31.30M and revenue of 189.30M, resulting in a net margin of -16.5%.
NVCR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, NovoCure Limited reported a net income of -34.32M and revenue of 154.99M, resulting in a net margin of -22.1%.